Objective To investigate the clinical effect of mosapride combined with omeprazole in the treatment of reflux esophagitis after surgery for esophageal carcinoma.Methods 84 patients with reflux esophagitis after surgery for esophageal cancer were randomly divided into an observation group and a control group.The observation group were treated with omeprazole (20mg,bid) and mosapride (5 mg,tid) and the control group with mosapride (5 mg,rid) for 2 months.Before and after the treatment,both groups were checked with gastroscope and scored.Results The heartburn,acid regurgitation,reflux,chest pain,and other clinical symptoms were significantly better and the symptom scores were lower after 2 months' treatment than before the treatment in the observation group,with statistical differences (t=4.821,P＜0.05).After the treatment,the symptom score was significantly lower in the observation group than in the control group,with a statistical difference (t=4.973,P ＜ 0.05);and each clinical symptom had been significantly improved.After 2 months' treatment,the clinical symptoms completely disappeared in 12 cases and almost disappeared in 23 cases in the observation group,with a total symptom remission rate of 83.3％,and 8 cases and 16 cases in the control group,with a total symptom remission rate of 57.1％.There was a statistical difference in total remission rate between these two groups (x 2=5.454,P ＜ 0.05).After treatment,the gastroscopic results showed that 24 cases were cured and 13 effective in the observation group,with a total efficacy of 88.1％,and 18 cured and 5 effective in the control group,with a total efficacy of 54.8％,with a statistical difference (x 2=5.312,P ＜ 0.05).Conclusions Mosapride combined with omeprazole in the treatment of reflux esophagitis after surgery for esophageal cancer is effective and has no serious adverse reactions.%目的 探讨莫沙必利联合奥美拉唑治疗食管癌术后反流性食管炎的临床效果.方法 将84例食管癌术后反流性食管炎患者随机分为观察组及对照组.观察组在治疗的2个月中,服用奥美拉唑(20 mg,bid)+莫沙必利(5mg,tid),对照组服用莫沙必利(5mg,tid).治疗前后进行胃镜检查,并进行评分.结果 经过2个月治疗后,观察组烧心、反酸、反流、胸痛等临床症状均得到了显著改善,症状评分显著降低,与治疗前相比,差异有统计学意义(t=4.821,P＜0.05).治疗后,观察组症状评分显著低于对照组,差异具有统计学意义(t=4.973,P＜0.05),各项临床症状均得到了显著改善.经过2个月临床治疗,观察组临床症状完全消失12例,基本消失23例,症状总缓解率为83.3％;对照组临床症状完全消失8例,基本消失16例,症状总缓解率为57.1％;两组症状总缓解率比较,差异具有统计学意义(x2=5.454,P＜0.05).治疗后胃镜检查结果显示,观察组治愈24例,有效13例,总有效率高达88.1％;对照组治愈18例,有效5例,总有效率54.8％;差异有统计学意义(x 2=5.312,P＜0.05).结论 莫沙必利联合奥美拉唑治疗食管癌术后反流性食管炎临床效果可靠,无严重不良反应.
展开▼
